Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    CAS-97519-39-6

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Basilea Gets $13M from BARDA for Ceftibuten-Ledaborbactam
    Basilea Gets $13M from BARDA for Ceftibuten-Ledaborbactam

    28 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/28/3302503/0/en/basilea-receives-further-usd-13-million-from-barda-to-continue-development-of-novel-antibiotic-ceftibuten-ledaborbactam.html

    GLOBENEWSWIRE
    28 May 2026
    Share Share
    Basilea Secures BARDA Contract For Ceftibuten-Ledaborbactam
    Basilea Secures BARDA Contract For Ceftibuten-Ledaborbactam

    25 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/25/3155972/0/en/Basilea-awarded-BARDA-contract-for-the-development-of-novel-oral-phase-3-ready-antibiotic-ceftibuten-ledaborbactam.html

    GLOBENEWSWIRE
    25 Sep 2025
    Share Share
    Basilea In-Licenses Novel Oral Antibiotic for Clinical Phase 3
    Basilea In-Licenses Novel Oral Antibiotic for Clinical Phase 3

    14 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/14/3133159/0/en/Basilea-announces-in-licensing-of-a-novel-clinical-phase-3-ready-oral-antibiotic.html

    GLOBENEWSWIRE
    14 Aug 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.